Table 1. Characteristics of OS patients.
| OS TMA | OS fresh frozen | |||
|---|---|---|---|---|
| All | FISH positive (out of 215 evaluable) | All | Intron 1 CN change | |
| Gender | 254/267 (95.1%) | 23/23 (100%) | 73/73 (100%) | 24/24 (100%) |
| male | 129 | 9 | 39 | 13 |
| female | 125 | 14 | 34 | 11 |
| Age at diagnosis | 258/267 (96.6%) | 23/23 (100%) | 73/73 (100%) | 24/24 (100%) |
| average | 24.3 years | 17 years | 17.3 years | 18.6 years |
| median | 17 years | 15 years | 15 years | 15.5 years |
| range | 4–88 years | 6–48 years | 3–56 years | 5–56 years |
| Observation period | 259/267 (97%) | 23/23 (100%) | 72/73 (98.6%) | 24/24 (100%) |
| average | 61.6 months | 46.6 months | 73.9 months | 64.6 months |
| median | 35 months | 24 months | 66.5 months | 64 months |
| range | 0–287 months | 0–179 months | 0–205 months | 2–196 months |
| Response to neoadjuvant treatment | 180/267 (67.4%) | 19/23 (83%) | 66/73 (90.4%) | 21/24 (87.5%) |
| good (< 10% viable tumor) | 102 | 14 | 35 | 10 |
| poor (≥ 10% viable tumor) | 78 | 5 | 31 | 11 |
| Metastases | 267/267 (100%) | 23/23 (100%) | 65/73 (89%) | 19/24 (79.2%) |
| yes | 101 | 9 | 39 | 10 |
| no | 166 | 14 | 26 | 9 |
| Survival | 259/267 (97%) | 23/23 (100%) | 72/73 (98.6%) | 24/24 (100%) |
| alive | 174 | 18 | 55 | 16 |
| deceased | 85 | 5 | 17 | 8 |
| TP53 immunhisto-chemistry | 212/267 (79.4%) | 19/23 (83%) | ||
| negative | 170 | 15 | ||
| positive | 42 | 4 | ||
| Location | 23/23 (100%) | 24/24 (100%) | ||
| femur | 14 | 12 | ||
| tibia | 5 | 8 | ||
| jaws | 2 | - | ||
| humerus | 1 | 1 | ||
| fibula | 1 | 1 | ||
| other | - | 2 | ||
OS TMA series / OS Fresh Frozen series: number of evaluable cases / total number of cases (percentage) CN, copy number